Aislinn Antrim, Managing Editor

SGLT-2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor are all showing promise in the prevention and management of diabetic kidney disease.

The test has been available under emergency use authorization (EUA) since March of 2020 and was the first commercial molecular test to receive EUA status.

The approval includes a novel dose and schedule of the combination, with a single dose of both drugs followed by durvalumab every 4 weeks in patients with unresectable hepatocellular carcinoma.

A more comprehensive body of regulations is required to achieve consistency and safety for patients.

Pharmacist involvement in identifying causes and treatment approaches is essential, as BCC can be a result of prior radiation therapy.

Neutralizing antibodies increased by 34- to 27-fold compared to pre-booster levels when administered at 8 or 11 months post-primary series.

The Moderna bivalent vaccine is authorized for children 6 years of age and older, and the Pfizer-BioNTech vaccine is authorized for children 5 years of age and older.

Treating patients with rivaroxaban resulted in 32.5 fewer symptomatic venous thromboembolism (VTE) and VTE-related deaths among 10,000 patients.

In a trial, sacituzumab govitecan-hziy demonstrated a 34% reduction in the risk of disease progression or death compared with physician’s choice chemotherapy.

Intravenous immunoglobulin was more effective than placebo, but not more effective than plasmapheresis and corticosteroids.

Rucaparib is the only PARP inhibitor demonstrated to have better outcomes than a docetaxel-containing control arm, according to researchers.

Women with a history of gestational diabetes had a 45% increased risk of overall cardiovascular and cerebrovascular diseases.

Aflibercept 8 mg demonstrated non-inferiority in vision gains in both the 12- and 16-week dosing regimens.

CDC Director Rochelle Walensky, MD, MPH, announced new preferential flu vaccine recommendations for individuals aged 65 years and older.

Respiratory infections have been associated with onset of type 1 diabetes in previous research, but this risk was notably higher among those with COVID-19 in this study.

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

All of the findings indicate that inadequate margin widths result in higher risks of distant recurrence and breast cancer mortality, as well as increased total recurrence.

Given that dendritic cells are necessary for anti-tumor response, researchers investigated which pathways stop these cells from performing their full functions.

Expert discusses whether epigenetic programs regulate human T cell exhaustion and whether epigenetic-based strategies can be used to enhance T cell-based therapies.

New research has shown significant promise for the use of CAR T-cell therapies in solid tumors.

Pfizer and BioNTech have also initiated a phase 1/2/3 study evaluating the safety, tolerability, and immunogenicity of different doses and dosing regimens with the vaccine in children.

The data showed moral concerns about fairness, loyalty, and purity influenced county-level vaccination rates, but care and authority did not.

The study also showed sustained reductions in hospitalizations over a 2-year period of FreeStyle Libre system use.

GENDER R25 will provide funding for courses and curricula to improve gender-focused education and equity in pharmacy, as well as other health care fields.

Pharmacists can educate older adults on risk factors and prevention efforts around herpes zoster.

Although there is no “best” way to determine which route of administration is best, health care providers are optimally positioned to educate patients and help them make the best decision.

Research indicates that poor technique or failure to follow up-to-date standards and protocols could lead to injury or even death of patients who need compounded medications.

Results demonstrated a 64.5% confirmed objective response rate in patients treated with the investigational combination.

Data presented at the 2022 ESMO congress show poziotinib has high activity in both treatment-naïve and previously treated patients with non-small cell lung cancer.

New results presented at the 2022 ESMO conference reinforce the potential of rucaparib as a first-line maintenance treatment option in a broad population of patients with ovarian cancer.